NCT06464692 - Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

Telisotuzumab Adizutecan

Intravenous (IV) Infusion

Trial Locations (8)

RECRUITING

Beijing Cancer Hospital /ID# 263297, Beijing

RECRUITING

First Affiliated Hospital of China Medical University /ID# 263338, Shenyang

RECRUITING

Harbin Medical University Cancer Hospital /ID# 263049, Harbin

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 263094, Hangzhou

RECRUITING

The First Affiliated Hospital of Nanchang University /ID# 263193, Nanchang

RECRUITING

Hubei Cancer Hospital /ID# 263248, Wuhan

RECRUITING

Henan Cancer Hospital /ID# 263172, Zhengzhou

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309, Guangzhou